fatty diacid chain raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-25 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Oral progesterone (Prometrium) metabolizes into neurosteroids including allopregnanolone and pregnanolone which act as potent GABAA receptor positive allosteric modulators. As a result, oral progesterone can dose-dependently produce side effects including dizziness, drowsiness, sedation, somnolence, fatigue, anxiety reduction, euphoria, and cognitive impairment. For this reason, oral progesterone is often taken at night before bed. Oral progesterone taken before bed has been found to improve multiple sleep outcomes in clinical studies. Zuranolone is a synthetic analogue of allopregnanolone that likewise acts as a GABAA receptor positive allosteric modulator but is orally active. It is under development for the treatment of insomnia and is in phase 3 clinical trials for this indication as of September 2025.
These cytosolic formyltransferase produce fMet-tRNAi, which can be used by cytosolic ribosomes to produce proteins with a N-terminal fMet. These proteins are targeted for degradation by specific processes in the cell.
=== Pharmacodynamics === Oxymorphone elicits its effects by binding to and activating the μ-opioid receptor (MOR) and, to a much lesser extent, the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). Its activity at the DOR may augment its action at the MOR. Oxymorphone is 10 times more potent than morphine. 1.02 mg of oxymorphone hydrochloride produces analgesia roughly equivalent to 10 mg of morphine sulfate, with similar peak and duration of effect but potentially slightly fewer side effects at equipotent doses.
Sources: en.wikipedia.org
Anterior vaginal wall prolapse Cystocele (bladder into vagina) Urethrocele (urethra into vagina) Cystourethrocele (both bladder and urethra) Posterior vaginal wall prolapse Enterocele (small intestine into vagina) Rectocele (rectum into vagina) Apical vaginal prolapse Uterine prolapse (uterus into vagina) Vaginal vault prolapse (roof of vagina) - after hysterectomy Pelvic floor dysfunction can result after treatment for gynecological cancers. Damage to the pelvic floor not only contributes to urinary incontinence but can also lead to pelvic organ prolapse. Pelvic organ prolapse occurs in women when pelvic organs (e.g. the vagina, bladder, rectum, or uterus) protrude into or outside of the vagina. The causes of pelvic organ prolapse are not unlike those that also contribute to urinary incontinence. These include inappropriate (asymmetrical, excessive, insufficient) muscle tone and asymmetries caused by trauma to the pelvis. Age, pregnancy, family history, and hormonal status all contribute to the development of pelvic organ prolapse. The vagina is suspended by attachments to the perineum, pelvic side wall and sacrum via attachments that include collagen, elastin, and smooth muscle. Surgery can be performed to repair pelvic floor muscles. The pelvic floor muscles can be strengthened with Kegel exercises. Disorders of the posterior pelvic floor include rectal prolapse, rectocele, perineal hernia, and several functional disorders, including anismus.
== Medically significant species == Mortality (often determined by measured toxicity on mice) is a commonly used indicator of the danger of any given venomous snake, but important too are efficiency of venom delivery, venom yield, and behavior upon encountering humans. Given these additional, practical concerns, many snake experts have cited the black mamba and the coastal taipan as the world's most dangerous snakes – even though their venoms, drop for drop, are not the most lethal. Both species are elapids, and in several aspects of morphology, ecology and behavior, the coastal taipan is strongly convergent with the black mamba.
Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart Campaign contributions at OpenSecrets.org Follow the Money – John Kennedy 2007 2005 2003 1999 Louisiana Treasurer campaign contributions
Systemic arterial pressures are generated by the forceful contractions of the heart's left ventricle. High blood pressure is a factor in causing arterial damage. Healthy resting arterial pressures are relatively low, mean systemic pressures typically being under 100 mmHg (1.9 psi; 13 kPa) above surrounding atmospheric pressure (about 760 mmHg, 14.7 psi, 101 kPa at sea level). To withstand and adapt to the pressures within, arteries are surrounded by varying thicknesses of smooth muscle which have extensive elastic and inelastic connective tissues. The pulse pressure, being the difference between systolic and diastolic pressure, is determined primarily by the amount of blood ejected by each heart beat, stroke volume, versus the volume and elasticity of the major arteries. A blood squirt, also known as an arterial gush, is the effect when an artery is cut due to the higher arterial pressures. Blood is spurted out at a rapid, intermittent rate, that coincides with the heartbeat. The amount of blood loss can be copious, can occur very rapidly, and be life-threatening. Over time, factors such as elevated arterial blood sugar (particularly as seen in diabetes mellitus), lipoprotein, cholesterol, high blood pressure, stress and smoking, are all implicated in damaging both the endothelium and walls of the arteries, resulting in atherosclerosis. Atherosclerosis is a disease marked by the hardening of arteries.
Sources: en.wikipedia.org
There is still much ongoing differential (DNA sequence based) comparison research that is trying to separate out the simplest forms of chordates. As some lineages that lack a backbone or notochord might have lost these structures over time, this complicates the classification of chordates. Some chordate lineages may only be identified by DNA analysis as there is no physical trace of any chordate-like structures. Attempts to work out the evolutionary relationships of the chordates have produced several hypotheses. The current consensus is that chordates are monophyletic (meaning, all chordates are descend from a single, common ancestor, which can be considered a chordate) and that the vertebrates' nearest relatives are tunicates. In 2016, identification of two conserved signature indels (CSIs) in the proteins cyclophilin-like protein and mitochondrial inner membrane protease ATP23, which are exclusively shared by all vertebrates, tunicates and cephalochordates also provided strong evidence of the monophyly of Chordata. All of the earliest chordate fossils have been found in the Early Cambrian Chengjiang fauna, and include three species that are regarded as fish, and hence vertebrates. Because the fossil record of early chordates is poor, only molecular phylogenetics offers a reasonable prospect of dating their emergence. However, the use of molecular phylogenetics for dating evolutionary transitions is controversial. It has proven difficult to produce a detailed classification within the living chordates.
=== 1.2 === DisplayPort version 1.2 was introduced on 7 January 2010. The most significant improvement of this version is the doubling of the data rate to 17.28 Gbit/s in High Bit Rate 2 (HBR2) mode, which allows increased resolutions, higher refresh rates, and greater color depth, such as 3840 × 2160 at 60 Hz 10 bpc RGB. Other improvements include multiple independent video streams (daisy-chain connection with multiple monitors) called Multi-Stream Transport (MST), facilities for stereoscopic 3D, increased AUX channel bandwidth (from 1 Mbit/s to 720 Mbit/s), more color spaces including xvYCC, scRGB, and Adobe RGB 1998, and Global Time Code (GTC) for sub 1 μs audio/video synchronisation. Also Apple Inc.'s Mini DisplayPort connector, which is much smaller and designed for laptop computers and other small devices, is compatible with the new standard.
=== Clinical diagnostics === Chilkoti has made contributions to biosensors and clinical diagnostics. His group was the first to demonstrate the use of surface-initiated polymerization to synthesize "nonfouling" polymer brushes from diverse surfaces that completely resist the adsorption of proteins and the adhesion of cells. He then used these nonfouling polymer brushes to develop a protein microarray that enables multiplexed detection of protein analytes with a femtomolar limit-of-detection directly from whole blood. Building upon this work, his group then invented the D4 point-of-care testing (POCT) technology, which enables rapid and accurate disease diagnosis by the quantitative measurement of multiple analytes at sub-picomolar concentrations from a drop of blood without user intervention. This technology led to the formation of a startup company —Sentilus—‚ that was acquired by Immucor in 2014. His group later used the D4 POCT for serology for COVID-19, COVID-19 variant detection, and detection of Ebolavirus.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.